BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29248128)

  • 1. Management of stage III non-small cell lung cancer.
    Tabchi S; Kassouf E; Rassy EE; Kourie HR; Martin J; Campeau MP; Tehfe M; Blais N
    Semin Oncol; 2017 Jun; 44(3):163-177. PubMed ID: 29248128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
    Casiraghi M; Maisonneuve P; Piperno G; Bellini R; Brambilla D; Petrella F; Marinis F; Spaggiari L
    Semin Thorac Cardiovasc Surg; 2017 Summer; 29(2):233-241. PubMed ID: 28823336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
    Ramnath N; Dilling TJ; Harris LJ; Kim AW; Michaud GC; Balekian AA; Diekemper R; Detterbeck FC; Arenberg DA
    Chest; 2013 May; 143(5 Suppl):e314S-e340S. PubMed ID: 23649445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
    Kunst PW; Lee P; Paul MA; Senan S; Smit EF
    J Thorac Oncol; 2007 Oct; 2(10):912-5. PubMed ID: 17909353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results].
    Schreiner W; Dudek W; Lettmaier S; Gavrychenkova S; Rieker R; Fietkau R; Sirbu H
    Zentralbl Chir; 2016 Jun; 141(3):323-9. PubMed ID: 27035568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined-modality therapy for lung cancer].
    Miura S; Yamamoto N
    Nihon Rinsho; 2010 Jun; 68(6):1121-8. PubMed ID: 20535966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.
    Antoni D; Mornex F
    Curr Opin Oncol; 2016 Mar; 28(2):104-9. PubMed ID: 26848885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
    Salama JK; Vokes EE
    J Clin Oncol; 2013 Mar; 31(8):1029-38. PubMed ID: 23401449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy for stage III non-small cell lung cancer: have we reached the limit?
    Xu P; Le Pechoux C
    Chin Clin Oncol; 2015 Dec; 4(4):45. PubMed ID: 26730757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality therapy for stage III non-small-cell lung cancer.
    Anderson CS; Curran WJ
    Semin Radiat Oncol; 2010 Jul; 20(3):186-91. PubMed ID: 20685581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.
    Kunitoh H; Suzuki K
    Br J Cancer; 2007 May; 96(10):1498-503. PubMed ID: 17473830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of non-small cell lung carcinoma].
    Souquet PJ
    Rev Prat; 2003 Apr; 53(7):747-51. PubMed ID: 12879798
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.